Erytech Pharma SA (EPA: ERYP) has appointed Alex Dusek as vice president of commercial strategy and member of the executive team, the biopharmaceutical company disclosed on Monday.
Dusek has 25 years of market access, product marketing and sales experience across small biotech start-ups and multi-national pharmaceutical companies.
Before joining Erytech, Dusek served as vice president of commercial strategy at Argos Therapeutics (OTCMKTS: ARGS). There he was responsible for pre-launch planning for the commercial distribution of an advanced cell therapy product.
His previous roles included leading global brand strategy at Bayer HealthCare Pharmaceuticals (ETR: BAYN) for the launch of a first-in-class, rare-disease agent, Adempas (riociguat). He was also United Therapeutics' (NASDAQ: UTHR) first marketing employee, building the company's marketing infrastructure and growing the pulmonary hypertension franchise.
Dusek will be based in the US, joining Erytech's expanding team in Cambridge, Massachusetts.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business